AstraZeneca Archives

News and Trends 20 Jan 2023

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics

The guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps. We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL. This week’s podcast […]

January 20, 2023

News and Trends 11 Jan 2023

AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma

Avillion LLP says the US Food and Drug Administration (FDA) has approved AstraZeneca’s Airsupra for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra, (albuterol/budesonide, formerly known as PT027) is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication […]

January 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

C2i Genomics extends AstraZeneca cancer deal

C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

New targeted drug shows benefit against breast cancer in first phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […]

December 9, 2022 - 7 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

December 9, 2022

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has entered into a definitive agreement to be acquired by Astrazeneca. AstraZeneca will acquire all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Nov 2022

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […]

November 18, 2022 - 3 minutesmins - By Liza Laws

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

November 14, 2022 - 9 minutesmins - By Jim Cornall

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

November 4, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

AstraZeneca

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics

AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma

C2i Genomics extends AstraZeneca cancer deal

New targeted drug shows benefit against breast cancer in first phase III trial

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

Enhertu’s positive results demonstrate improvement in overall survival

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!